EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Accessing Promising Passerini Adducts in Anticancer Drug Design

Ana Margarida Janeiro iD, Aday González-Bakker iD, José M Padrón iD, Carolina S Marques iD

Molecules · 2024

DOI: 10.3390/molecules29235538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Ana Margarida Janeiro und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, Spanish Government, Asociación Española Contra el Cáncer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 3-component Passerini reaction (3CPR), discovered little more than 100 years ago, has been demonstrated in the last few decades to be a valuable tool for accessing structural diversity and complexity, essential topics to consider in drug discovery programs. Focusing on accessing a fine-tuned family of α-acyloxyamide–oxindole hybrids, we underline herein our latest insights regarding the use of this mild reaction approach to obtain promising anticancer agents. Cheap and commercially available isatin was used as starting material. The library of α-acyloxyamide–oxindole hybrids was tested against six human solid-tumor cell lines; among them, non-small cell lung carcinoma, cervical and colon adenocarcinoma, and breast and pancreas cancer. The most potent compound displayed GI50 values in the range of 1.3–21 µM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug DesignHumansCell Line, TumorDrug Screening Assays, AntitumorMolecular StructureStructure-Activity RelationshipOxindolesCell Proliferation

Stichwörter der Autor:innen

GI50Passerini-3Ccancerdrug designisatinoxindole

Substanzen

Antineoplastic AgentsOxindoles

Autor:innen und Institutionen

  • Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal.
  • BioLab, Instituto Universitario de Bio-Orgánica Antonio González (IUBO-AG), Universidad de La Laguna, P.O. Box 456, 38200 La Laguna, Spain.
  • LAQV-REQUIMTE, Institute for Research and Advanced Studies, University of Évora, Rua Romão Ramalho, 59, 7000-641 Évora, Portugal.

ORCID-Profile: Ana Margarida Janeiro, Aday González-Bakker, José M Padrón, Carolina S Marques

Förderung

  • Fundação para a Ciência e Tecnologia
  • Spanish Government
  • Asociación Española Contra el Cáncer
  • Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES)

Zitieren

APA

Janeiro, A. M., González-Bakker, A., Padrón, J. M., & Marques, C. S. (2024). Accessing Promising Passerini Adducts in Anticancer Drug Design. Molecules. https://doi.org/10.3390/molecules29235538

Vancouver

Janeiro AM, González-Bakker A, Padrón JM, Marques CS. Accessing Promising Passerini Adducts in Anticancer Drug Design. Molecules. 2024. doi:10.3390/molecules29235538

BibTeX
@article{Janeiro2024,
  author = {Janeiro, Ana Margarida and González-Bakker, Aday and Padrón, José M and Marques, Carolina S},
  title = {Accessing Promising Passerini Adducts in Anticancer Drug Design},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29235538}
}
Kostenlos starten →